A lung nodule is a small, roughly round spot in the lung, usually less than 3 centimeters across, that shows up on a chest CT scan or X-ray. Finding out you have one can be alarming, but the vast majority turn out to be harmless: more than 95% of lung nodules found incidentally on CT are benign.1PubMed Central. Incidental Pulmonary Nodules: Differential Diagnosis and Clinical Management That said, the small fraction that are cancerous makes careful evaluation essential, and how doctors handle that evaluation has changed considerably in recent years.
How Lung Nodules Get Discovered
Most lung nodules are found by accident. You go in for a CT scan after a car accident, a heart workup, or persistent back pain, and the radiologist spots a small white dot in your lung that nobody was looking for. These are called incidental pulmonary nodules. A review of 24 studies covering nearly 31,000 people who had CT scans for reasons unrelated to cancer found that nodule prevalence varied widely depending on how much of the chest the scan captured and what size threshold doctors used to flag a nodule as worth mentioning.2PubMed. Prevalence of pulmonary nodules detected incidentally on noncancer-related imaging: a review Cardiac CT scans, which capture part of the lung field, are one of the most common ways nodules get picked up unexpectedly.
The other pathway is lung cancer screening. If you are between 50 and 80, have a significant smoking history, and still smoke or quit within the past 15 years, you may qualify for annual low-dose CT screening. The American College of Radiology developed a standardized system called Lung-RADS to categorize screen-detected nodules, ranging from clearly benign (category 1) to highly suspicious (category 4).3PubMed. ACR Lung-RADS v2022: Assessment Categories and Management Recommendations Whether your nodule was found through screening or by accident shapes how your doctor decides what to do next, because screening populations tend to have a higher baseline risk of lung cancer than people who had scans for unrelated reasons.
Why Most Nodules Are Benign
The list of harmless things that can form a small round shadow in the lung is surprisingly long. Old infections are the most common culprit. If you have ever had pneumonia, tuberculosis, or a fungal infection like histoplasmosis, the aftermath can leave a small scar or a calcified granuloma that sits quietly in the lung for decades. Hamartomas, which are benign clusters of normal tissue types that grew in an unusual spot, are another frequent finding.4PubMed Central. The calcified lung nodule: What does it mean? Lymph nodes inside the lung, small areas of inflammation, or even a pocket of mucus can all present as nodules on imaging.
Calcification patterns are one of the quickest reassuring signs a radiologist looks for. A nodule with dense, central, or “popcorn-style” calcification is almost always benign. The texture, shape, and location of the nodule all feed into the initial impression. A smooth, round, solidly calcified spot in the middle of the lung is about as low-risk as it gets. The trouble starts when a nodule has none of those reassuring features.
Features That Raise Concern
Radiologists evaluate several visual characteristics to gauge whether a nodule deserves a closer look. Size is the single most important factor. Nodules smaller than 6 millimeters in people without major risk factors rarely need follow-up at all. As size increases, so does the probability that the nodule could be malignant. A nodule over 2 centimeters gets substantially more scrutiny.
Shape matters too. The spiculation sign, where a nodule’s edges have spiky, star-like projections radiating outward, is one of the strongest visual clues pointing toward malignancy.5PubMed Central. Spiculation Sign Recognition in a Pulmonary Nodule Based on Spiking Neural P Systems One study that analyzed multiple imaging traits found that a combination of size, contour shape, concavity, and texture could distinguish malignant from benign nodules with roughly 81% accuracy. When size was excluded from the model, features like lobulation, spiculation, and whether the nodule was attached to a fissure (the thin membrane separating lung lobes) still achieved about 73% accuracy.6Clinical Cancer Research. Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules
Nodule density also tells a story. Solid nodules are completely opaque on a CT scan. Ground-glass nodules look hazy, like frosted glass, because they only partially fill the air spaces. Part-solid nodules have both a hazy region and a dense core. Part-solid nodules that develop a growing solid component tend to carry the highest per-nodule malignancy risk, even though pure ground-glass nodules can also represent early-stage cancers that grow very slowly.
How Doctors Decide What to Do Next
The Fleischner Society guidelines, updated in 2017, are the most widely used framework for managing incidentally found nodules. The revised version raised the minimum size threshold below which no routine follow-up is needed, gave recommended follow-up intervals as ranges rather than fixed dates, and combined solid and subsolid nodule guidance into one simplified table.7PubMed. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017 The idea was to reduce unnecessary repeat scans for tiny, low-risk nodules while giving doctors and patients more flexibility to account for individual circumstances.8PubMed. Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging Scenarios
In practice, the guidelines sort patients into low-risk and high-risk categories based on factors like smoking history, family history of lung cancer, and nodule characteristics. A low-risk patient with a single solid nodule under 6 millimeters generally needs no follow-up at all. A high-risk patient with a part-solid nodule over 6 millimeters will likely be asked to come back for repeat imaging in 3 to 6 months. If the nodule grows or develops a larger solid component, the timeline accelerates toward PET scanning or biopsy.
Risk Prediction Models
When a nodule falls into an ambiguous category, doctors sometimes use mathematical models to estimate the probability of cancer. The most established are the Mayo Clinic model, the Brock University model, and the Herder model (which adds PET scan results to the calculation). These tools crunch patient age, smoking status, nodule size, location, and other features into a percentage likelihood of malignancy.
How well do they work? In a validation study comparing all three, the models performed similarly, with area-under-the-curve values hovering around 0.67 to 0.73, meaning they do better than a coin flip but are far from perfect.9PubMed Central. Comparison of Brock University, Mayo Clinic and Herder models for pretest probability of cancer in solid pulmonary nodules A separate study in a high-risk cohort found Brock and Mayo tied at about 0.70, with the Herder model performing best at 0.77 in patients who also had PET-CT data available.10CHEST Pulmonary. The Lung Cancer Prediction Model “Stress Test”: Assessment of Models’ Performance in a High-Risk Prospective Pulmonary Nodule Cohort Another validation found the Mayo and Brock models performing somewhat better, around 0.90, with the Brock model edging ahead for nodules under one centimeter.11PubMed. Risk of malignancy in pulmonary nodules: A validation study of four prediction models The variability across studies tells you something important: these models are helpful decision-support tools, not oracles. They work best when combined with a radiologist’s judgment and the full clinical picture.
Growth Rate and What It Means
One of the most reliable signals that a nodule needs attention is growth over time. Doctors measure this using volume doubling time, or how long it takes for the nodule’s volume to double. In a lung cancer screening study, malignant solid nodules that were growing had a median doubling time of about 204 days, while benign growing nodules doubled in roughly 386 days.12PubMed Central. Volume Doubling Times of Benign and Malignant Nodules in Lung Cancer Screening The catch is that some benign nodules do grow, and the doubling times overlap, so growth alone does not always cinch the diagnosis.
Nodule type affects growth speed. Solid malignant nodules tend to double fastest, with a mean doubling time around 230 to 267 days. Part-solid malignant nodules grow more slowly (roughly 462 to 598 days), and pure ground-glass malignant nodules are the most sluggish, with doubling times often exceeding 650 days.13PubMed Central. Malignant solitary pulmonary nodules: assessment of mass growth rate and doubling time at follow-up CT This is why ground-glass nodules sometimes get watched for years without intervention. They may technically harbor early cancer cells, but many grow so slowly that immediate treatment provides no survival advantage over careful monitoring.
PET Scans and Their Limitations
When a nodule is large enough or suspicious enough that more information is needed before deciding on biopsy, a PET-CT scan is often the next step. PET scans work by detecting areas of high metabolic activity, which cancers tend to have. The combined PET-CT approach has shown accuracies around 91% for distinguishing malignant from benign lung lesions in screening-detected nodules, with high specificity around 95%.14PubMed. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT One earlier study found that combining PET and CT data raised accuracy from about 74% (using either alone) to 93%.15Journal of Nuclear Medicine. Accuracy of PET/CT in Characterization of Solitary Pulmonary Lesions
PET scans have a well-known blind spot, though: infections. Active infections, especially fungal infections, light up on PET scans just like cancers do. A meta-analysis found that in regions where infectious lung diseases are common, PET specificity dropped to about 61%, compared to 77% in areas without endemic infections.16PubMed Central. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: A meta-analysis If you live in the Ohio or Mississippi River valleys (histoplasmosis territory), the Southwest (coccidioidomycosis), or the Upper Midwest (blastomycosis), a hot PET scan does not necessarily mean cancer.17PubMed. Thoracic Endemic Fungi in the United States: Importance of Patient Location In fact, there is a specific imaging pattern called the “fungal flip-flop sign,” where lymph nodes light up more intensely than the nodule itself, that has near-perfect specificity for fungal infection when paired with positive blood tests for the fungus.18CHEST Pulmonary. Chest Infections: CHEST Pulmonary Reviews Endemic Mycoses for Pulmonary Clinicians: From Nodules to ARDS
When a Biopsy Is Needed
If imaging and risk models leave the diagnosis uncertain, a tissue sample resolves the question. There are two main biopsy approaches for lung nodules: CT-guided transthoracic needle biopsy, where a needle is inserted through the chest wall, and navigational bronchoscopy, where a thin scope is threaded through the airways to reach the nodule from inside the lung.
A recent randomized trial published in the New England Journal of Medicine compared the two head-to-head. Navigational bronchoscopy achieved a diagnostic accuracy of about 79%, while transthoracic biopsy came in at roughly 74%, meeting the threshold for noninferiority. The big difference was complications. The transthoracic approach caused pneumothorax (a collapsed lung from air leaking into the chest cavity) in about 28% of cases, and roughly 12% of those patients needed a chest tube or hospital admission. By contrast, navigational bronchoscopy caused pneumothorax in only about 3% of patients, with under 1% needing a chest tube.19PubMed Central. Navigational Bronchoscopy versus Transthoracic Biopsy for Lung Nodules That substantial safety advantage has pushed many centers to favor bronchoscopy-first approaches for nodules that are reachable through the airways.
A smaller single-institution retrospective study found lower bronchoscopy accuracy (about 57%) compared to transthoracic biopsy (about 76%), though the complication rate was still higher in the needle biopsy group.20PubMed Central. CT-Guided vs. Navigational Bronchoscopic Biopsies for Solitary Pulmonary Nodules: A Single-Institution Retrospective Comparison Performance depends on the nodule’s location, the equipment available, and the expertise of the operator. A peripheral nodule far from major airways may be easier to reach with a needle, while a centrally located one is a natural fit for bronchoscopy.
If a Nodule Turns Out to Be Cancer
For the small percentage of nodules that prove to be early-stage non-small cell lung cancer, surgical removal remains the standard treatment for patients healthy enough to undergo it. A large observational study found that five-year overall survival after surgery ranged from about 48% to 65%, depending on the type of resection, compared with about 30% for stereotactic body radiation therapy (SBRT).21JAMA Network Open. Comparison of Long-term Survival of Patients With Early-Stage Non–Small Cell Lung Cancer After Surgery vs Stereotactic Body Radiotherapy For patients who cannot tolerate surgery due to poor lung function or other medical conditions, SBRT is considered standard of care and delivers focused, high-dose radiation directly to the tumor over a few treatment sessions.22PubMed Central. Current evidence and ongoing trials for surgery versus stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer: a narrative review
The Overdiagnosis Problem
More screening and better CT scanners mean more nodules found, and that has raised a legitimate concern: overdiagnosis. Some lung cancers detected through screening are so slow-growing that they would never have caused symptoms or death in the patient’s lifetime. An analysis from the National Lung Screening Trial found that overdiagnosis was about 17% among stage IA cancers. Much of this was concentrated in a specific category of tumors now classified as adenocarcinoma in situ, minimally invasive adenocarcinoma, or adenocarcinoma of low malignant potential. These subtypes exhibited 100% disease-specific survival over seven years, meaning no one died from the cancer itself.23PubMed Central. Pulmonary adenocarcinoma of low malignant potential defines indolent NSCLC associated with overdiagnosis in the national lung screening trial
The clinical challenge is distinguishing a truly indolent cancer from one that will eventually progress. Right now, there is no test that reliably separates them at the moment of diagnosis, which means some patients undergo surgery for a cancer that would have sat there harmlessly. Researchers are working on genetic and imaging markers to identify the indolent ones, but for now the honest answer is that a small amount of overtreatment is baked into screening programs.
Nodules in People Who Have Never Smoked
Getting told you have a lung nodule can be especially unsettling if you have never smoked, because the instinct is to think nodules are a “smoker’s problem.” They are not. Never-smokers develop lung nodules for many of the same benign reasons that anyone else does: prior infections, inflammation, or benign growths. When nodules in never-smokers do turn out to be cancer, the biology tends to be different. Ground-glass nodules in never-smokers are more commonly driven by EGFR mutations, which were found in 64% of samples in one study of ground-glass nodules. EGFR-mutated nodules were more likely to grow and to represent invasive disease.24PubMed. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth Meanwhile, some nodules carrying KRAS or BRAF mutations may actually shrink on their own.25PubMed Central. Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights
The practical takeaway for never-smokers: a lung nodule does not mean you have lung cancer, and current screening programs are not designed for you (they target people with significant smoking histories). If a nodule was found incidentally, follow-up decisions should be guided by the same Fleischner criteria used for anyone else, adjusted for your individual risk factors.
The Emotional Weight of Waiting
One aspect that rarely makes it into the medical literature as prominently as it should is the psychological toll of being told you have a lung nodule and then being asked to wait months or years for repeat scans. In one study using a validated distress measure, about a third of patients with newly found small nodules reported at least mild distress, and roughly 7% experienced severe distress.26PubMed. Emotional Distress, Anxiety, and General Health Status in Patients With Newly Identified Small Pulmonary Nodules: Results From the Watch the Spot Trial Qualitative research paints a vivid picture: patients described being “shocked,” “scared,” and finding it hard to cope with the uncertainty of a surveillance period that could stretch for years.27BMJ Open. Patients’ experiences of, and psychological responses to, surveillance for pulmonary nodules detected through lung cancer screening
People respond differently over time. Most eventually come to accept that their nodule is unlikely to be malignant, but some remain persistently anxious, convinced the nodule could turn into cancer at any moment and wanting aggressive monitoring indefinitely.28PubMed Central. ‘The thing is not knowing’: patients’ perspectives on surveillance of an indeterminate pulmonary nodule If this describes you, it is worth mentioning to your doctor. The anxiety is normal, it is well-documented, and there are ways to address it, from more thorough explanations of your actual risk to referral for anxiety management if needed. A study looking at shared decision-making found that patients whose role in decision-making matched their preference reported higher satisfaction with care and perceived better quality of care, even though it did not necessarily improve their knowledge about the nodule itself.29PubMed Central. Association of Decision-making with Patients’ Perceptions of Care and Knowledge during Longitudinal Pulmonary Nodule Surveillance Feeling involved in the plan matters, even when the plan is “watch and wait.”
Blood Tests and AI on the Horizon
Two technological fronts are advancing quickly. The first is blood-based biomarker testing, sometimes called liquid biopsy. The idea is to identify proteins, circulating tumor cells, or DNA fragments in the blood that could help distinguish a dangerous nodule from a harmless one without needing a tissue biopsy. One blood test, Nodify CDT, has shown high specificity (91% to 97%) across a pooled analysis of more than 1,100 patients, meaning it produces very few false alarms when it says a nodule is low risk.30PubMed Central. A multivariate cell-based liquid biopsy for lung nodule risk stratification: Analytical validation and early clinical evaluation These tests are still being refined and are not yet standard care, but they point toward a future where a blood draw could spare patients both unnecessary biopsies and months of anxious surveillance.
The second frontier is artificial intelligence applied to CT images. Deep learning models trained on thousands of nodule images have reached impressive accuracy in distinguishing malignant from benign nodules, with some reporting accuracy above 90% and area-under-the-curve values around 0.96.31PubMed Central. Efficient pulmonary nodules classification using radiomics and different artificial intelligence strategies Another model using a dual-attention mechanism reported an F1-score above 95%.32Scientific Reports. Effective lung nodule detection using deep CNN with dual attention mechanisms These tools are being developed as decision aids for radiologists, not replacements. The real-world performance in diverse patient populations and across different scanner types still needs more validation, but the trajectory suggests that AI-assisted nodule reading will become routine within the next several years.
When Geography Muddies the Picture
Where you live can meaningfully affect how a lung nodule gets interpreted. In the Ohio and Mississippi River valleys, histoplasmosis is so common that many adults have been exposed without knowing it, and the lung scars it leaves behind are one of the most frequent causes of benign nodules in the region. Coccidioidomycosis plays the same role in the American Southwest. These fungal nodules can mimic cancer on CT and even on PET scans, where active or chronic infections light up with metabolic activity.17PubMed. Thoracic Endemic Fungi in the United States: Importance of Patient Location
Occupational exposures add another layer. A study of underground mine workers exposed to radon found lung nodules in about 31% of workers who underwent low-dose CT scanning.33Journal of Radiation Research and Applied Sciences. Study of the occupational health risk of radon exposure in underground workers in a mine Radon exposure is a recognized risk factor for lung cancer, so nodules in these workers carry a different risk calculus than the same-size nodule in someone without occupational exposure. The broader point is that your personal history, your geography, and your occupational environment all feed into what a lung nodule means for you specifically, which is why blanket reassurance like “95% are benign” is true at the population level but only your doctor can tell you what the number is for your individual case.